Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Adicet Bio, Inc. (TORC) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2023 8-K Quarterly results
Docs: "Adicet Reports Second Quarter 2023 Financial Results and Provides Business Updates Announced encouraging safety and efficacy data in ongoing Phase 1study of ADI-001 for the potential treatment of relapsed or refractory B-cell non-Hodgkin’s lymphoma On track to report a clinical update for ADI-001 in second half of 2024 Plan to file Investigational New Drug Application for ADI-925 in H2 2023 and ADI-270 in H1 2024 Strong balance sheet with $205.5 million in cash and cash equivalents as of June 30, 2023 REDWOOD CITY, Calif. & BOSTON – August 9, 2023 – Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights for the second quarter ended June 30, 2023. &#x..."
05/09/2023 8-K Quarterly results
Docs: "Adicet Reports First Quarter 2023 Financial Results and Provides Business Updates On track to report additional efficacy, durability and safety data and provide a regulatory update and plan for ADI-001 pivotal program in 2Q 2023 Strong balance sheet with $231.6 million in cash, cash equivalents and investments as of March 31, 2023 Redwood City, Calif. and BOSTON – May 9, 2023 – Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights for the first quarter ended March 31, 2023. “We are excited about the continued clinical progress of our lead asset ADI-001,” said Chen Schor, President and Chief Executive Officer of Adicet. “In the s..."
11/08/2022 8-K Quarterly results
Docs: "Adicet Reports Third Quarter 2022 Financial Results and Provides Business Updates As of ASH abstract data-cut date, ADI-001 demonstrated a positive safety and efficacy profile; Company to provide more recent data cut from its ongoing Phase 1study during ASH Annual Meeting Company to host ADI-001 webcast event on December 11, 2022 at 9:00 a.m. ET On track to initiate a potentially pivotal program for ADI-001 in the first half of 2023 Strong balance sheet with $282.7 million in cash and cash equivalents as of September 30, 2022; Cash runway into first half of 2025 Company to host R&D webcast event detailing four new pipeline candidates on November 10, 2022 at 9:00 a.m. ET REDWOOD CITY, Calif. and BOSTON – November 8, 2022 – Adicet Bio, Inc. , a clinical stage biotechnology company discoverin..."
08/10/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
11/10/2021 8-K Quarterly results
Docs: "Adicet Reports Third Quarter 2021 Financial Results and Provides Business Updates  On track to report top-line safety and tolerability data from ADI-001 Phase 1study in Non-Hodgkin's Lymphoma by year end  Announced collaboration with Twist Bioscience to accelerate discovery of gamma delta T cell cancer therapeutics and expand pipeline Menlo Park, CA and Boston, MA – November 10, 2021 – Adicet Bio, Inc. , a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today reported operational highlights and financial results for the third quarter ended September 30, 2021. “Over the third quarter, Adicet has made steady progress in advancing the first-in-human Phase 1 trial of our lead asset, AD..."
08/12/2021 8-K Quarterly results
Docs: "Adicet Reports Second Quarter 2021 Financial Results and Provides Business Updates On track to report top-line interim data from ADI-001 Phase 1study in Non-Hodgkin's Lymphoma by the end of 2021 Menlo Park, CA and Boston, MA – August 12, 2021 – Adicet Bio, Inc. , a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today reported operational highlights and financial results for the second quarter ended June 30, 2021. “Adicet continues to build momentum over the second quarter, following the initiation of our Phase 1 trial of our lead asset ADI-001 in non-Hodgkin’s lymphoma and the completion of a successful capital raise earlier this year. We believe we are in a strong position to execute on key upco..."
05/17/2021 8-K/A Quarterly results
Docs: "Adicet Reports First Quarter 2021 Financial Results and Provides Business Updates"
05/17/2021 8-K Quarterly results
Docs: "Adicet Reports First Quarter 2021 Financial Results and Provides Business Updates"
11/05/2020 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Adicet Reports Third Quarter 2020 Financial Results and Provides Business Update Menlo Park, CA and Boston, MA - November 5, 2020 - Adicet Bio, Inc. , a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today reported financial results for the third quarter ended September 30, 2020. “We are extremely proud of the milestones we've achieved this quarter, including the completion of the merger between Adicet Bio and resTORbio, the clearance of our IND application for ADI-001, and the expansion of our executive team with the appointment of Nick Harvey as CFO and, more recently, Don Healey, Ph.D., as CTO,” said Chen Schor, President and Chief Executive Officer of Adicet. “Looking ahead, we expect to initiate th..."
07/30/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
Docs: "R&D Expenses: Research and development expenses were $4.8 million for the three months ended March 31, 2020 compared to $8.9 million for the three months ended March 31, 2019. The decrease was primarily due to the reduction in the number of ongoing clinical trials. • G&A Expenses: General and administrative expenses were $2.5 million for the three months ended March 31, 2020 compared to $2.8 million for the three months ended March 31, 2019. The decrease was primarily due to a decrease in headcount partially offset by higher facilities-related expenses. • Net Loss: Net loss was $7.0 million, or $0.19 per share, for the three months ended March 31, 2020 compared to a net loss of $11.1 million, or $0.38 per share, for the three months ended March 31, 2019. • Cash, Cash E..."
03/12/2020 8-K Quarterly results
Docs: "R&D Expenses: Research and development expenses were $26.1 million for the three months ended December 31, 2019 and $73.6 million for the year ended December 31, 2019, as compared to $4.3 million for the three months ended December 31, 2018 and $31.1 million for the year ended December 31, 2018. The increase in R&D expenses year-over-year was primarily due to the Company’s Phase 3 PROTECTOR program for clinically symptomatic respiratory illness, now discontinued, and, to a lesser extent, the ongoing Phase 1b/2a for Parkinson’s disease. • G&A Expenses: General and administrative expenses were $3.3 million for the three months ended December 31, 2019 and $11.8 million for the year ended December 31, 2019, as compared to $2.0 million for the three months ended December 31, 2018 and $8...."
11/05/2019 8-K Quarterly results
08/14/2019 8-K Quarterly results
Docs: "RTB101 Phase 3 PROTECTOR Program in Clinically Symptomatic Respiratory Illness Advancing Ahead of Previously Disclosed Clinical Timelines: During the second quarter, resTORbio initiated a global Phase 3 PROTECTOR program in adults 65 years of age and older, excluding current smokers and chronic pulmonary disease patients. The program consists of two randomized, double-blind, placebo-controlled clinical trials to evaluate the safety and efficacy of RTB101 10 mg given orally once daily for 16 weeks during winter cold and flu season. The primary endpoint of both trials is the reduction in the percentage of patients with clinically symptomatic respiratory illness, defined as illness associated with a respiratory tract infection based on prespecified diagnostic criteria. In July 2019, the compa..."
05/15/2019 8-K Quarterly results
Docs: "R&D Expenses: Research and development expenses were $8.9 million for the three months ended March 31, 2019 compared to $8.1 million for the three months ended March 31, 2018. The increase was primarily due to the initiation of the Phase 1b/2a for Parkinson’s disease and preparation for the Phase 3 clinical program for clinical symptomatic respiratory illness. • G&A Expenses: General and administrative expenses were $2.8 million for the three months ended March 31, 2019 compared to $2.1 million for the three months ended March 31, 2018. The increase was primarily due to an increase in headcount as well as increased operating costs as a result of the Company’s transition from a private company to a public company, including legal, accounting, insurance and investor relations expenses...",
"resTORbio Appoints Lloyd Klickstein, M.D., Ph.D., as Chief Scientific Officer"
03/18/2019 8-K Quarterly results
Docs: "R&D Expenses: Research and development expenses were $4.3 million for the three months ended December 31, 2018 and $31.1 million for the year ended December 31, 2018, as compared to $6.8 million for the three months ended December 31, 2017 and $16.8 million for the year ended December 31, 2017. The increase in R&D expenses year-over-year was primarily due to the Company’s completed Phase 2b trial in RTIs and preparations for its Phase 3 clinical trials. • G&A Expenses: General and administrative expenses were $2.0 million for the three months ended December 31, 2018 and $8.6 million for the year ended December 31, 2018, as compared to $0.7 million for the three months ended December 31, 2017 and $2.0 million for the year ended December 31, 2017. The increase in G&A expenses year-ove..."
11/13/2018 8-K Quarterly results
Docs: "R&D Expenses: R&D expenses were $6.8 million for the three months ended September 30, 2018 compared to $3.3 million for the three months ended September 30, 2017. The increase was primarily attributable to the Company’s Phase 2b trial. • G&A Expenses: General and administrative expenses were $2.3 million for the three months ended September 30, 2018 compared to $0.6 million for the three months ended September 30, 2017. The increase was primarily attributable to an increase in headcount as well as increased operating costs as a result of the Company’s transition from a private company to a public company, including legal, accounting, insurance and investor relations expenses. • Net Loss: Net loss was $8.4 million, or $0.30 per share, for the three months ended September 30, 2..."
08/09/2018 8-K Quarterly results
Docs: "R&D Expenses: R&D expenses were $11.8 million for the three months ended June 30, 2018 compared to $3.4 million for the three months ended June 30, 2017. The increase was primarily attributable to the Company’s Phase 2b study. • G&A Expenses: General and administrative expenses were $2.3 million for the three months ended June 30, 2018 compared to $0.6 million for the three months ended June 30, 2017. The increase was primarily attributable to an increase in headcount as well as increased operating costs as a result of the Company’s transition from a private company to a public company, including legal, accounting, insurance and investor relations expenses. • Net Loss: Net loss was $13.6 million, or $0.48 per share, for the three months ended June 30, 2018 compared to a net l..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy